Effects of Dan-Shao-Hua-Xian on the expression of collagen type I and III in rats with hepatic fibrosis

Hepatobiliary and Pancreatic Diseases International

Volumn 3, Issue 4, 2004, Pages 558-563

  Geng, Xiao Xia ^a   Yang, Qin ^a   Xie, Ru Jia ^a   Luo, Xin Hua ^b   Li, Cheng Xiu ^a   Cheng, Ming Liang ^a  

^a GUIZHOU MEDICAL UNIVERSITY   (China)

^b People's Hospital of Guizhou Province   (China)

Author keywords

Collagen; Hyaluronic acid; Hydroxyproline; Liver fibrosis; Traditional Chinese herbs

Indexed keywords

ALANINE AMINOTRANSFERASE; ASTRAGALUS MEMBRANACEUS EXTRACT; CARBON TETRACHLORIDE; CHINESE DRUG; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DAN SHAO HUA XIAN; GINKGO BILOBA EXTRACT; HERBACEOUS AGENT; HYALURONIC ACID; HYDROXYPROLINE; PAEONIA RADIX; SALVIA MILTIORRHIZA EXTRACT; TETRANDRINE; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHINESE MEDICINE; CONTROLLED STUDY; DISEASE MODEL; DISEASE SEVERITY; DOSE RESPONSE; DRUG MECHANISM; GENE EXPRESSION; LIVER FIBROSIS; MALE; MEDICINAL PLANT; NONHUMAN; PROTEIN RESTRICTION; RANDOMIZATION; RAT; RAT STRAIN; TETRANDINE; TREATMENT OUTCOME; URINARY EXCRETION;

ALANINE TRANSAMINASE; ANIMALS; COLLAGEN TYPE I; COLLAGEN TYPE III; DRUGS, CHINESE HERBAL; HYALURONIC ACID; HYDROXYPROLINE; LIVER; LIVER CIRRHOSIS; MALE; MEDICINE, CHINESE TRADITIONAL; ORGAN SIZE; RATS; RATS, WISTAR;

EID: 9444272773     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Yan JC, Ma Y, Chen WB, Sun XH. Dynamic observation on liver fibrosis and cirrhosis of hepatitis B. Huaren Xiaohua Zazhi 1998;6:699-702.
2. Weng HL, Cai WM, Liu RH. Animal experiment and clinical study of effect of gamma 2 interferon on hepatic fibrosis. World J Gastroenterol 2001;7:42-48.
3. 4 -induced liver fibrosis in rats. Chin Public Health 1998;14:527-529.
4. Zhang HN, Li CX, Huang NH, Luo J, Cheng ML. The preventive actions of traditional Chinese medicine Han-Dan-Gan-Le on porcine serum-induced liver fibrosis in rats. Guizhou Med J 2001;25:415-417.
5. Cheng ML, Ding YS, Luo YF, Tian M, Wu J, Luo TY, et al. The clinical research of the therapeutic effects of Han-Dan-Bi-Tuo on chronic active hepatitis. Chin J Trad-Western Med 1996;16:431-432.
6. Cheng ML, Yang CQ. The basic study and clinical research on hepatic fibrosis. Los Angeles: First Jumbo Publishing Co,2002.
7. Bissell DM. Connective tissue metabolism and hepatic fibrosis: an overview. Semi Liver Dis 1990;10:III-iv
8. Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aube C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997;113:1609-1614.
9. Zheng M, Cai WM, Weng HL, Liu RH. Roc curve in evaluation of serum fibrosis index for diagnosing hepatic fibrosis. Chin J Infect Dis 2002;20:225-227.
10. Ding HB, Chen YP, Feng XR, Liu DL, Wu AH, Zhang L. Correlation between liver fibrosis stage and serum liver fibrosis markers in patients with chronic hepatitis B. Chin J Hepatol 2001;9:78-80.
11. 4-induced liver fibrosis in rats. Acta Academiae Medicinae Militaris Tertiae 1996;18:234-236.
12. Gao CF, Ye WM, Xu LL, Xue C, Tu XQ, Fan LY, et al. Application of serum markers in the diagnosis of fibrotic liver disease. Chin J Lab Med 2001;24:91-93.
13. Zhang SL, Yang YP, Chen DY, Song XX, Yang SC, Wang CW. The diagnostic meaning of HA, PIIIP, IV-C, LN and PGA in liver fibrosis. Chin J Infect Dis 1999;17:261-262.
14. Li BS, Wang J, Liu JX, Sun SQ, Wei MX, Liu XM, et al. The preliminary study on diagnostic value of co-detection of serum PCIII, HA and LN in liver fibrosis patients. Chin J Infect Dis 1998;16:85-87.
15. Xie SB, Yao JL, Zheng RQ, Peng XM, Gao ZL. Serum hyaluronic acid, procollagen type III and IV in histolopical diagnosis of liver fibrosis. Hepatobiliary Pancreat Dis Int 2003;2:69-72.
16. Xie SB, Yao JL, Zheng SS, Yao CL, Zheng RQ. The levels of serum fibrosis marks and morphometric quantitative measurement of hepatic fibrosis. Hepatobiliary Pancreat Dis Int 2002;1: 202-206.
17. Xu GG, Luo CY, Wu SM, Wang CL. The relationship between staging of hepatic fibrosis and the levels of serum biochemistry. Hepatobiliary Pancreat Dis Int 2002;1:246-248.
18. Liu C, Jiang CM, Liu CH, Liu P, Hu YY. Effect of Fuzhenghuayu decoction on vascular endothelial growth factor secretion in hepatic stellate cells. Hepatobiliary Pancreat Dis Int 2002;1: 207-210.
19. Schuppan D. Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins. Semin liver Dis 1990;10:1-10.
20. Wu YY, Cheng ML, Lu T, Ding YS, Wu J, Lu YY, et al. Effect of Han-Dan-Gan-Le on the proliferation of fat-storing cell of mouse liver. Guizhou Med J 2000;24:15-16.
21. Luo Y, Dai LL, Shen DM. The new study of the hepatic stellate cell and hepatic fibrosis. Chin J Hepatol 2000;8:251-252.
22. Alcolado R, Arthur MJP, Iredale JP. Pathogenesis of liver fibrosis. Clin Sci 1997;92:103-112.
23. Friedman SL. Molecular mechanisms of hepatic fibrosis and principle of therapy. J Gastroenterol 1997;32:424-430.
24. Williams EJ, Iredale JP. Liver cirrhosis. Postgrad Med J 1998; 74:193-202.
25. Wu J, Zern MA. Hepatic stellate cells: a target for the treatment of liver fibrosis. J Gastroenterol 2000;35:665-672.
26. Zhao JF, Liu CH, Hu YY, Xu LM, Liu P, Liu C. Effect of salvianolic acid B on Smad3 expression in hepatic stellate cells. Hepatobiliary Pancreat Dis Int 2004;3:102-105.
27. Cheng YX, Zhang XR, Xie WF, Li S. Effects of taurine on proliferation and apoptosis of hepatic stellate cells in vitro. Hepatobiliary Pancreat Dis Int 2004;3:106-109.
28. Friedman SL. The cellular basis of hepatic fibrosis: mechanisms and treatment strategies. N Engl J Med 1993;328:1828-1835.
29. Jiang CM, Liu C, Liu P. The developing researches of the HSC during liver fibrosis. Chin J Digestol 2000;20:258-260.
30. Olaso E, Friedman SL. Molecular regulation of hepatic fibrogenesis. J Hepatol 1998;29:836-847.
31. Friedman SL. Cytokines and fibrogenesis. Semin Liver Dis 1999;19:129-140.